A Phase III, Open-label, Randomised Study of Osimertinib With or Without Datopotamab Deruxtecan (Dato-DXd), as First-line Treatment in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer

This study is testing a new way to treat a specific type of lung cancer by combining two targeted therapies. Researchers want to see if adding a new drug, Dato-DXd, to the standard treatment, Osimertinib, works better than taking the standard treatment alone.

You may be eligible if you are 18 or older and have recently been diagnosed with advanced non-small cell lung cancer that has specific 'EGFR' genetic changes. You must not have received previous systemic treatment for this cancer, and you must be in generally good health regarding your heart, eyes, and digestive system.

You will be assigned to receive either the standard pill treatment alone or a combination of the pill and an infusion of the new medication. You will visit the clinic regularly for check-ups and monitoring to track how your cancer responds to the treatment.

The study is currently recruiting volunteers at multiple locations in California, including Fountain Valley, Los Alamitos, and Los Angeles. It is a long-term study that will track participants over several years.